TELEFLEX INC【TFX】
時価総額
$53.9億
PER
医療機器メーカーの大手。UroLiftなどの尿路治療製品、血管介入・血管アクセス製品を展開。2017年にNeoTractとVascular Solutionsを買収、2025年2月にBIOTRONIKのVI事業を初期対価€760百万で買収合意。米国・欧州・アジアで展開。
| 2010年 12月31日 | 2011年 12月31日 | 2012年 12月31日 | 2013年 12月31日 | 2014年 12月31日 | 2015年 12月31日 | 2016年 12月31日 | 2017年 12月31日 | 2018年 12月31日 | 2019年 12月31日 | 2020年 12月31日 | 2021年 12月31日 | 2022年 12月31日 | 2023年 12月31日 | 2024年 12月31日 | |
| Net revenues | - | - | - | - | - | - | - | - | 2,448 | 2,595 | 2,537 | 2,810 | 2,791 | 2,974 | 3,047 |
| Cost of goods sold | - | - | - | - | - | - | - | - | 1,064 | 1,104 | 1,212 | 1,260 | 1,260 | 1,328 | 1,345 |
| Gross profit | 794 | 719 | 748 | 839 | 942 | 944 | 996 | 1,172 | 1,384 | 1,492 | 1,325 | 1,550 | 1,531 | 1,647 | 1,703 |
| Selling, General and Administrative Expense | 475 | 429 | 454 | 502 | 579 | 569 | 563 | 700 | 879 | 934 | 744 | 860 | 864 | 930 | 995 |
| Research and Development Expense | 43 | 49 | 56 | 65 | 61 | 52 | 59 | 85 | 106 | 114 | 120 | 131 | 154 | 154 | 162 |
| Pension settlement charge | - | - | - | - | - | - | - | - | - | - | - | - | - | -45 | -133 |
| Goodwill, Impairment Loss | - | - | 332 | - | - | - | - | - | - | - | - | - | - | - | 240 |
| Restructuring And Impairment Provisions | - | - | - | - | - | - | - | - | - | - | - | - | - | 16 | 22 |
| Gain on sale of assets and business | - | - | - | - | - | - | - | - | 1 | 6 | - | 91 | 7 | 4 | - |
| Income from continuing operations before interest, loss on extinguishment of debt and taxes | 274 | 233 | -97 | 233 | 285 | 316 | 319 | 372 | 322 | 427 | 423 | 628 | 500 | 506 | 151 |
| Interest expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 84 |
| Interest income | 1 | 1 | 2 | 1 | 1 | 1 | 0 | 1 | 1 | 2 | 1 | 1 | 1 | 13 | 8 |
| Loss on extinguishment of debt | -47 | -15 | - | -1 | - | -10 | -19 | -6 | - | -9 | - | -13 | -0 | - | - |
| Income from continuing operations before taxes | - | 149 | -165 | 176 | 220 | 245 | 246 | 285 | 220 | 340 | 358 | 559 | 446 | 434 | 75 |
| Income Tax Expense (Benefit) | 22 | 27 | 16 | 24 | 29 | 8 | 8 | 130 | 23 | -122 | 22 | 74 | 83 | 76 | 5 |
| Income from continuing operations | 126 | 122 | -182 | 152 | 191 | 237 | 238 | 155 | 196 | 462 | 336 | 485 | 363 | 358 | 70 |
| Operating (loss) income from discontinued operations | 126 | 289 | -9 | -2 | -3 | -2 | -1 | -5 | 6 | -1 | -1 | 0 | 0 | -2 | -1 |
| Discontinued Operation, Tax Effect of Discontinued Operation | 49 | 86 | -2 | -2 | -1 | -11 | -1 | -2 | 1 | -0 | -0 | 0 | 0 | -0 | -0 |
| (Loss) income from discontinued operations | 77 | 203 | -7 | -0 | -3 | 9 | 0 | -3 | 4 | -1 | -0 | 0 | 0 | -1 | -0 |
| Net income | 202 | 325 | -189 | 152 | 189 | 246 | 238 | 153 | 201 | 461 | 335 | 485 | 363 | 356 | 70 |
| Income from continuing operations (in dollars per share) | 3.12 | 2.98 | -4.47 | 3.68 | 4.6 | 5.68 | 5.47 | 3.45 | 4.3 | 10 | 7.22 | 10.37 | 7.74 | 7.61 | 1.5 |
| (Loss) income from discontinued operations (in dollars per share) | 1.92 | 5 | -0.18 | -0.01 | -0.06 | 0.21 | 0.01 | -0.06 | 0.09 | -0.01 | -0.01 | 0.01 | - | -0.03 | -0.01 |
| Net income (in dollars per share) | 5.04 | 7.98 | -4.65 | 3.67 | 4.54 | 5.89 | 5.48 | 3.39 | 4.39 | 9.99 | 7.21 | 10.38 | 7.74 | 7.58 | 1.49 |
| Income from continuing operations (in dollars per share) | 3.09 | 2.96 | -4.47 | 3.46 | 4.1 | 4.91 | 4.98 | 3.33 | 4.2 | 9.81 | 7.1 | 10.23 | 7.67 | 7.56 | 1.49 |
| (Loss) income from discontinued operations (in dollars per share) | 1.9 | 4.97 | -0.18 | -0.01 | -0.06 | 0.19 | - | -0.06 | 0.09 | -0.01 | -0.01 | - | 0.01 | -0.03 | -0.01 |
| Net income (loss), diluted (in dollar per share) | 4.99 | 7.92 | -4.65 | 3.45 | 4.04 | 5.1 | 4.98 | 3.27 | 4.29 | 9.8 | 7.09 | 10.23 | 7.68 | 7.53 | 1.48 |